Drug development for CNS disorders: strategies for balancing risk and reducing attrition.
about
Biomarkers predicting antidepressant treatment response: how can we advance the field?Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury.Induced Pluripotent Stem Cell Models to Enable In Vitro Models for Screening in the Central Nervous SystemHistopathologic characterization of the BTBR mouse model of autistic-like behavior reveals selective changes in neurodevelopmental proteins and adult hippocampal neurogenesisA novel neurotrophic drug for cognitive enhancement and Alzheimer's diseaseRemoving obstacles in neuroscience drug discovery: the future path for animal models.Zebrafish behavioral profiling identifies multitarget antipsychotic-like compounds.Preclinical assessment of CNS drug action using eye movements in mice.Meeting the unique challenges of drug discovery for neurodegenerative diseasesZebrafish behavioral profiling links drugs to biological targets and rest/wake regulation.A derivative of platelet-derived growth factor receptor alpha binds to the trimer of human cytomegalovirus and inhibits entry into fibroblasts and endothelial cellsFilling the gap in CNS drug development: evaluation of the role of drug repurposing.Identification of marine neuroactive molecules in behaviour-based screens in the larval zebrafishPredicting harms and benefits in translational trials: ethics, evidence, and uncertainty.Back to the future with phenotypic screeningA method to predict blood-brain barrier permeability of drug-like compounds using molecular dynamics simulationsNIMH initiatives to facilitate collaborations among industry, academia, and government for the discovery and clinical testing of novel models and drugs for psychiatric disordersPotent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.Seven challenges for neuroscienceWhy so few drugs for Alzheimer's disease? Are methods failing drugs?Optimized turmeric extract reduces β-Amyloid and phosphorylated Tau protein burden in Alzheimer's transgenic miceNovel drugs and therapeutic targets for severe mood disorders.A broadly neuroprotective derivative of curcumin.The effect of nanoparticle size on the probability to cross the blood-brain barrier: an in-vitro endothelial cell modelWhy do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?SVM Based Descriptor Selection and Classification of Neurodegenerative Disease Drugs for Pharmacological Modeling.Diffusion of macromolecules in the brain: implications for drug delivery.Retinal Electrophysiology Is a Viable Preclinical Biomarker for Drug Penetrance into the Central Nervous System.Neuropsychiatric clinical trials: should they accommodate real-world practices or set standards for clinical practices?Use of functional imaging across clinical phases in CNS drug development.Design of a novel thiophene inhibitor of 15-lipoxygenase-1 with both anti-inflammatory and neuroprotective propertiesChemobehavioural phenomics and behaviour-based psychiatric drug discovery in the zebrafishMass spectrometry-based neurochemical analysis: perspectives for primate research.Omics approaches to individual variation: modeling networks and the virtual patientTranslating Stem Cell Biology Into Drug Discovery.Alzheimer's disease drug development: old problems require new priorities.Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances?Lost in translation: neuropsychiatric drug development.Was phenserine a failure or were investigators mislead by methods?New therapeutic potential for psychoactive natural products.
P2860
Q27026147-2DD33AE0-B911-497C-9D30-385FAEFEFB90Q27311418-1B0A2C45-8CCC-4088-85B6-64A7DA6D62D8Q28082668-4ADA96D7-159D-4EE8-BE0A-6BE843256679Q28390236-73CFB711-1FBB-47E3-82F6-7374DD58F1FDQ28478380-DDBF5B6D-DFBE-4BA5-95DC-7A9AE67F6F7DQ28755229-0A9132C8-4056-40F6-BAE8-263950E76336Q30369007-AD847F69-9624-405E-A913-E302749E67ECQ30503853-F61EFFC6-6A5D-4B43-A53C-B14E75EE6231Q33469818-A0CDDEE8-99D7-44AB-B53E-6CE8612BBD35Q33523962-8392634C-6C6C-47EE-A8A1-61F69E1482A2Q33558900-99344772-46BD-49B0-B31F-F4D1DD32286EQ33604666-440927E6-A06E-48F3-85F7-6F8E90EE36A7Q33808929-222FCD9E-7BBC-4601-ABEF-7D06F4D41F2AQ33851241-30644712-FAFA-498C-9186-471049D25430Q33918218-EAB49F21-9EE1-4538-90DA-A61EE79FE939Q34031018-788F3715-2F22-4327-9855-FD1169802BD8Q34050607-9EEF36B7-23EC-4EAE-8D4A-BD02304BA13DQ34221351-94CEC030-4FEB-45C0-BC82-3D2038BB0DE5Q34378681-65288F91-C646-4740-9050-7779E593C571Q34440659-1089D8BC-2E0A-4C04-850B-093A07FC5166Q34631904-1F6C7F6C-11B2-45E4-8DC7-A82518024CBAQ34732759-46A579BB-335A-466F-B171-82F3B3CD3382Q34738787-5FAAC912-F7B7-41AB-AB30-8102C652CC88Q35177868-E09674A8-F055-4FC5-A38C-E0902A61112BQ36022784-4D4AB3B4-D896-4898-9752-5245F6D479EFQ36092174-29AA0091-AA70-4969-8005-E6D38AC84F9FQ36823757-D4E51766-AA8F-42E8-841C-50803885CF53Q36889744-6AC1F0EC-8BB3-43C0-8141-7E521ABC207EQ37055784-04757E8D-97F8-469D-AFA8-91B4E515F41DQ37065259-28106F84-E88B-4868-86D3-D6C750B081BFQ37229746-329FAD25-8B4F-43D7-ABA3-A1A057EE53B0Q37265890-B43B5247-433D-4488-A6A7-6127B4C39095Q37304110-8F7D2990-1876-4DF8-99A2-7E6E1F273D8DQ37344759-1F943312-B283-41E6-835D-7289EC53749DQ37356503-2CA88E86-D9BE-49BE-8680-0AB37F5969E2Q37363992-8D465600-21CC-4566-8B33-E85F3BCE2FE7Q37524877-0AD958C8-BD1A-4C38-91E5-C514D187519DQ37527193-60E87F9F-AD4C-4835-AE02-E40BF8891F4AQ37530878-4B4C9C0D-D3AF-421C-B935-D45B15BCB8B1Q37660087-8C65B684-360F-4E19-A591-26FD5C21E313
P2860
Drug development for CNS disorders: strategies for balancing risk and reducing attrition.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Drug development for CNS disorders: strategies for balancing risk and reducing attrition.
@en
type
label
Drug development for CNS disorders: strategies for balancing risk and reducing attrition.
@en
prefLabel
Drug development for CNS disorders: strategies for balancing risk and reducing attrition.
@en
P2093
P2860
P356
P1476
Drug development for CNS disorders: strategies for balancing risk and reducing attrition.
@en
P2093
Lee E Schechter
Menelas N Pangalos
Orest Hurko
P2860
P2888
P304
P356
10.1038/NRD2094
P577
2007-07-01T00:00:00Z